Christopher E. Dandoy, MD, MSc
- Member, Division of Bone Marrow Transplantation and Immune Deficiency
- Associate Professor, UC Department of Pediatrics
- christopher.dandoy@cchmc.org
- Board Certified
About
Biography
I have always enjoyed caring for patients and their families, and I appreciate the unique bond that forms during treatment. But as a physician, I’ve experienced the devastating impact bloodstream infections can have on children. On more than one occasion, my team has successfully cured a child’s cancer using stem cell transplant, only to lose them later to a bloodstream infection.
As a result, my research focuses on identifying, testing and implementing clinical strategies to help improve outcomes after stem cell transplantation for malignancy. My clinical work compliments my research focus since I am the physician lead for the autologous stem cell transplant program, caring for many patients with leukemia. I prioritize patient safety, quality improvement, and the prevention of bloodstream infections and cardiopulmonary complications, such as pulmonary hypertension.
Cincinnati Magazine recognized me as a Top Doctor in 2019 and 2020. Also, our Cancer and Blood Diseases Institute Quality Improvement and Patient Safety team won the Ohio Patient Safety Institute’s Dr. Frank Dono Best Practice Award.
I am co-editor of the book Patient Safety and Quality in Pediatric Hematology/Oncology and Stem Cell Transplantation, published in 2017 by Springer. I’ve served in several local and national leadership roles, including the co-physician lead for the Solutions for Patient Safety (SPS) Pediatric Hematology-Oncology Central Line-Associated Bloodstream Infection (CLABSI) reduction collaboration.
I serve as the vice chair of the American Society of Transplant and Cellular Therapy (ASTCT) Committee on Quality Outcomes. I am co-chair of the Center for International Blood and Marrow Transplant Research (CIBMTR) Infection and Immune Reconstitution Working Committee.
BS: Weber State University, Ogden, UT, 2003.
MD: University of Utah, Salt Lake City, UT, 2007.
MSc: University of Cincinnati, Cincinnati, OH, 2014.
Residency: Miami Children’s Hospital, Miami, FL, 2010.
Chief Residency: Miami Children’s Hospital, Miami, FL, 2011.
Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2014; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2014.
Certification: Pediatrics, 2010; Pediatric Hematology Oncology, 2015.
Interests
Hematopoietic stem cell transplantation for children and young adults with malignancy or hemoglobinopathies
Services and Specialties
Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Cardio-Oncology
Additional Languages
Portuguese, Spanish
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortality. Frontiers in Oncology. 2023; 13:1232621.
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?. Blood Reviews. 2023; 60:101079.
Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2023; 2:1151744.
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer. 2023; 70:e30271.
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.
The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study. Bone Marrow Transplantation. 2023; 58:360-366.
Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment. Cancer. 2023; 129:1064-1074.
Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Transplantation and cellular therapy. 2023; 29:282.e1-282.e9.
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplantation and cellular therapy. 2023; 29:151-163.
Go to bed!: Sleep as a risk factor for adolescent hypertension. Progress in Pediatric Cardiology. 2023; 68:101613.
From the Blog
For Children After Stem Cell Transplants, Food Timing Matters
Christopher E. Dandoy, MD, MSc, YunZu Michele Wang, MD ...2/15/2023
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2023 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey